Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CASP3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CASP3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CASP3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CASP3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CASP3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003425022 | Liver | HCC | positive regulation of cellular amide metabolic process | 110/7958 | 162/18723 | 5.14e-11 | 1.92e-09 | 110 |
GO:005134822 | Liver | HCC | negative regulation of transferase activity | 166/7958 | 268/18723 | 8.97e-11 | 3.18e-09 | 166 |
GO:004254222 | Liver | HCC | response to hydrogen peroxide | 100/7958 | 146/18723 | 1.79e-10 | 6.15e-09 | 100 |
GO:001624111 | Liver | HCC | regulation of macroautophagy | 96/7958 | 141/18723 | 6.82e-10 | 2.14e-08 | 96 |
GO:003367322 | Liver | HCC | negative regulation of kinase activity | 144/7958 | 237/18723 | 9.76e-09 | 2.45e-07 | 144 |
GO:000193322 | Liver | HCC | negative regulation of protein phosphorylation | 196/7958 | 342/18723 | 1.95e-08 | 4.63e-07 | 196 |
GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
GO:007099722 | Liver | HCC | neuron death | 202/7958 | 361/18723 | 1.44e-07 | 2.70e-06 | 202 |
GO:000646912 | Liver | HCC | negative regulation of protein kinase activity | 126/7958 | 212/18723 | 4.55e-07 | 7.49e-06 | 126 |
GO:190121412 | Liver | HCC | regulation of neuron death | 179/7958 | 319/18723 | 5.65e-07 | 9.01e-06 | 179 |
GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
GO:007121421 | Liver | HCC | cellular response to abiotic stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
GO:010400421 | Liver | HCC | cellular response to environmental stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CASP3 | SNV | Missense_Mutation | novel | c.576N>A | p.Asp192Glu | p.D192E | P42574 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
CASP3 | deletion | Frame_Shift_Del | | c.768_799delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Lys259HisfsTer19 | p.K259Hfs*19 | P42574 | protein_coding | | | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CASP3 | SNV | Missense_Mutation | | c.768T>G | p.Phe256Leu | p.F256L | P42574 | protein_coding | tolerated(0.07) | benign(0.232) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CASP3 | SNV | Missense_Mutation | | c.517N>C | p.Glu173Gln | p.E173Q | P42574 | protein_coding | tolerated(0.37) | possibly_damaging(0.585) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CASP3 | SNV | Missense_Mutation | | c.159G>T | p.Lys53Asn | p.K53N | P42574 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
CASP3 | SNV | Missense_Mutation | novel | c.428N>C | p.Phe143Ser | p.F143S | P42574 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CASP3 | SNV | Missense_Mutation | | c.491G>A | p.Arg164His | p.R164H | P42574 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CASP3 | SNV | Missense_Mutation | novel | c.184N>G | p.Thr62Ala | p.T62A | P42574 | protein_coding | tolerated(0.74) | benign(0.001) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CASP3 | SNV | Missense_Mutation | rs776881401 | c.73N>A | p.Glu25Lys | p.E25K | P42574 | protein_coding | tolerated(1) | benign(0) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CASP3 | SNV | Missense_Mutation | novel | c.34N>G | p.Ser12Ala | p.S12A | P42574 | protein_coding | tolerated(0.07) | benign(0.001) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | celecoxib | CELECOXIB | 22336956 |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | SPERMINE | SPERMINE | 18366176 |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | activator | 178101922 | | |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | PACLITAXEL | PACLITAXEL | 9067280 |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | AICAR | CHEMBL483849 | 17181154 |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | WITHAFERIN A | WITHAFERIN A | 22705001 |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 178103141 | | |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | IPRIFLAVONE | IPRIFLAVONE | |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | 1,4-DICHLOROBENZENE | 1,4-DICHLOROBENZENE | 16699520 |
836 | CASP3 | DRUGGABLE GENOME, PROTEASE, ENZYME | | 5,6,7-TRIBROMOISATIN | CHEMBL376616 | 17088067 |